RHYTHM PHARMACEUTICALS, INC. (RYTM) Form 10-Q — Nov 3, 2026
Rhythm Pharmaceuticals reported Q3 2026 revenue of $92.1 million, up 80% year over year, driven by the U.S. launch of IMCIVREE in acquired hypothalamic obesity, which won FDA approval in March 2026. Net loss narrowed to $41.4 million from $52.9 million a year ago. The company held $320.9 million in cash and short-term investments at quarter end and says existing resources fund operations through at least 24 months.
Key figures
- Revenue
- 92128000
- Revenue Yoy
- 79.6% YoY (Q3 2026 $92.1M vs Q3 2025 $51.3M); 9M 2026 $223.5M vs $132.5M
- Total Assets
- 443132000
- Shares Outstanding
- 69330906
- Cash runway
- at least 24 months from filing
- Term loan rate
- Adjusted Term SOFR + 4.60% (1.00% SOFR floor)
- Net loss 9m 2026
- 146306000
- Term loan capacity
- 750000000
- Term loan maturity
- November 2, 2031
- Us revenue q3 2026
- 67500000
- Accumulated deficit
- 1498183000
- Ex us revenue q3 2026
- 24700000
- Lgc amendment payments
- 350000000
- Term loan initial tranche
- 250000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.